Articles related to IMMUNOTHERAPY

As yet, there are no consensus treatment strategies for class 2 and 3 BRAF mutations. This systematic review and meta-analysis of published reports of patients with class 2 or 3 BRAF mutations from 2010 to 2021 assesses MAPK targeted therapy in the setting. The meta-analysis suggests that MAPK TTs have clinical activity in some class 2 and 3 BRAF-mutant cancers.

In patients with advanced-stage, untreated follicular lymphoma (FL), the RELEVANCE trial demonstrated that rituximab plus chemotherapy (R-chemo) and lenalidomide plus rituximab (R2) had comparable efficacy (FL). After six years of follow-up, a report on the second interim analysis of the RELEVANCE experiment is presented here.

The differences between bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy, the side effects of bispecific antibodies, how the antibodies may address unmet needs in lymphoma, and a few other observations are discussed in this interview with Dr. John N. Allan, Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine in New York.

Talking about the limitations of the International Workshop on CLL (iwCLL) response criteria for chronic lymphocytic leukemia (CLL) in the era of novel medications is Dr. Alexey V. Danilov, Professor and Co-Director of the Toni Stephenson Lymphoma Center at the City of Hope National Medical Center in Duarte, California.

Reversal of HLA-I loss is crucial for an effective antitumor cytotoxic T cell response. Thus, HLA-I–upregulating drugs could augment immunotherapy response. The authors describe here a small-molecule USP7 inhibitor as a promising avenue for pharmacologic upregulation of HLA-I in MCC.

The meta-analysis included data from nearly 13,000 patients across 30 published trials. Grade 3 or 4 AEs occurred in nearly 70% of patents receiving TKIs compared with 37% for those receiving ICIs.